Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hellenic Oncology Research Group
With
University Hospital of Crete
Age
18–75
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed breast adenocarcinoma.
Within 20-45 days after the surgical excision of the primary tumor with tumor-free operation margins; at least 10 axillary lymph nodes have to be removed.
Absence of lymph node involvement after eclosion and hormone (E\&H) staining and light microscopy evaluation.
Premenopausal or postmenopausal women with at least one of the following tumor characteristics is required in order to characterize the tumor as high risk:
* Estrogen receptor (ER) (-) and progesterone receptor (PR)(-);
* Ki-67 + \> 30%; Grade III; HER2 (3+) (after an amendment on 15.05.2008 women with HER2 (3+) were not included); Perineural infiltration or presence of tumor emboli in blood or lymph vessels.
Premenopausal and postmenopausal women with tumors measuring \> 2 cm are eligible irrespectively of the expression of the above adverse prognostic tumor criteria.
Absence of any clinical or radiological evidence of local or metastatic disease.
Age \> 18 years.
Performance status (WHO) \< 3.
Adequate bone marrow function (absolute neutrophil count \> 1000/mm\^3, platelet count \> 100000/mm\^3, hemoglobin \> 9 gr/mm\^3).
Adequate liver (bilirubin \< 1.5 times upper limit of normal and SGOT/SGPT \< 2 times upper limit of normal) and renal function (creatinine \< 2 mg/dl).
Adequate cardiac function (LVEF \> 50%).
Negative pregnancy test.
Informed consent.
You may not be if
Other invasive malignancy within the past 5 years except nonmelanoma skin cancer.
Other concurrent uncontrolled illness that could affect compliance with the study.
Psychiatric illness or social situation that would preclude study compliance.
Pregnant or nursing women.
History of allergic reaction attributed to docetaxel.
Other concurrent investigational agents.
Clareo Health | Epirubicin and Docetaxel Combination (ET) or Epirubicin Followed by Docetaxel (E/T) for Node Negative (N0) High Risk Breast Cancer Patients
